Guilin Sanjin Pharmaceutical Co Ltd (002275) - Net Assets

Latest as of September 2025: CN¥3.24 Billion CNY ≈ $474.83 Million USD

Based on the latest financial reports, Guilin Sanjin Pharmaceutical Co Ltd (002275) has net assets worth CN¥3.24 Billion CNY (≈ $474.83 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥4.30 Billion ≈ $629.19 Million USD) and total liabilities (CN¥1.05 Billion ≈ $154.36 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Guilin Sanjin Pharmaceutical Co Ltd's assets to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥3.24 Billion
% of Total Assets	75.47%
Annual Growth Rate	9.1%
5-Year Change	1.72%
10-Year Change	28.45%
Growth Volatility	28.3

Guilin Sanjin Pharmaceutical Co Ltd - Net Assets Trend (2006–2024)

This chart illustrates how Guilin Sanjin Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Guilin Sanjin Pharmaceutical Co Ltd (002275) total assets for the complete picture of this company's asset base.

Annual Net Assets for Guilin Sanjin Pharmaceutical Co Ltd (2006–2024)

The table below shows the annual net assets of Guilin Sanjin Pharmaceutical Co Ltd from 2006 to 2024. For live valuation and market cap data, see Guilin Sanjin Pharmaceutical Co Ltd market capitalisation.

Year	Net Assets	Change
2024-12-31	CN¥3.01 Billion ≈ $440.42 Million	+6.84%
2023-12-31	CN¥2.82 Billion ≈ $412.21 Million	+0.13%
2022-12-31	CN¥2.81 Billion ≈ $411.68 Million	-0.93%
2021-12-31	CN¥2.84 Billion ≈ $415.55 Million	-4.03%
2020-12-31	CN¥2.96 Billion ≈ $433.00 Million	+5.10%
2019-12-31	CN¥2.82 Billion ≈ $411.99 Million	+0.31%
2018-12-31	CN¥2.81 Billion ≈ $410.70 Million	+5.76%
2017-12-31	CN¥2.65 Billion ≈ $388.35 Million	+9.41%
2016-12-31	CN¥2.43 Billion ≈ $354.94 Million	+3.52%
2015-12-31	CN¥2.34 Billion ≈ $342.87 Million	+0.97%
2014-12-31	CN¥2.32 Billion ≈ $339.57 Million	+5.33%
2013-12-31	CN¥2.20 Billion ≈ $322.38 Million	+6.02%
2012-12-31	CN¥2.08 Billion ≈ $304.06 Million	+4.79%
2011-12-31	CN¥1.98 Billion ≈ $290.15 Million	+10.17%
2010-12-31	CN¥1.80 Billion ≈ $263.37 Million	+0.95%
2009-12-31	CN¥1.78 Billion ≈ $260.89 Million	+126.51%
2008-12-31	CN¥787.10 Million ≈ $115.18 Million	+7.93%
2007-12-31	CN¥729.25 Million ≈ $106.71 Million	+16.25%
2006-12-31	CN¥627.33 Million ≈ $91.80 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Guilin Sanjin Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 272.5% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	CN¥1.46 Billion	48.37%
Common Stock	CN¥587.57 Million	19.52%
Other Comprehensive Income	CN¥397.95 Million	13.22%
Other Components	CN¥568.52 Million	18.89%
Total Equity	CN¥3.01 Billion	100.00%

Guilin Sanjin Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Guilin Sanjin Pharmaceutical Co Ltd ranked by their market capitalization.

Company	Market Cap
Guild Holdings Co NYSE:GHLD	$1.25 Billion
Equital TA:EQTL	$1.25 Billion
Taysha Gene Therapies Inc NASDAQ:TSHA	$1.25 Billion
RES.MINING UNSP.ADR/10 F:RSM0	$1.25 Billion
INKON Life Technology Co Ltd SHE:300143	$1.25 Billion
Leon's Furniture Limited TO:LNF	$1.25 Billion
Charoen Pokphand Enterprise Taiwan Co Ltd TW:1215	$1.24 Billion
Castellana Properties Socimi MC:YCPS	$1.24 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Guilin Sanjin Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 2,816,961,724 to 3,009,775,751, a change of 192,814,027 (6.8%).
Net income of 521,533,564 contributed positively to equity growth.
Dividend payments of 336,142,884 reduced retained earnings.
Other comprehensive income decreased equity by 5,556,809.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	CN¥521.53 Million	+17.33%
Dividends Paid	CN¥336.14 Million	-11.17%
Other Comprehensive Income	CN¥-5.56 Million	-0.18%
Other Changes	CN¥12.98 Million	+0.43%
Total Change	CN¥-	6.84%

Book Value vs Market Value Analysis

This analysis compares Guilin Sanjin Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 2.82x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 12.35x to 2.82x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2006-12-31	CN¥1.17	CN¥14.49	x
2007-12-31	CN¥1.36	CN¥14.49	x
2008-12-31	CN¥1.47	CN¥14.49	x
2009-12-31	CN¥3.20	CN¥14.49	x
2010-12-31	CN¥3.05	CN¥14.49	x
2011-12-31	CN¥3.33	CN¥14.49	x
2012-12-31	CN¥3.51	CN¥14.49	x
2013-12-31	CN¥3.71	CN¥14.49	x
2014-12-31	CN¥3.93	CN¥14.49	x
2015-12-31	CN¥3.98	CN¥14.49	x
2016-12-31	CN¥4.13	CN¥14.49	x
2017-12-31	CN¥4.51	CN¥14.49	x
2018-12-31	CN¥4.75	CN¥14.49	x
2019-12-31	CN¥4.81	CN¥14.49	x
2020-12-31	CN¥5.14	CN¥14.49	x
2021-12-31	CN¥4.94	CN¥14.49	x
2022-12-31	CN¥4.79	CN¥14.49	x
2023-12-31	CN¥4.81	CN¥14.49	x
2024-12-31	CN¥5.14	CN¥14.49	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Guilin Sanjin Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 17.33%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 23.77%
• Asset Turnover: 0.52x
• Equity Multiplier: 1.41x
Recent ROE (17.33%) is below the historical average (18.19%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2006	31.46%	24.42%	0.96x	1.34x	CN¥132.89 Million
2007	34.57%	27.90%	0.83x	1.50x	CN¥177.10 Million
2008	35.17%	27.76%	0.85x	1.50x	CN¥195.90 Million
2009	17.06%	27.23%	0.54x	1.16x	CN¥125.18 Million
2010	14.44%	26.31%	0.50x	1.11x	CN¥79.58 Million
2011	14.72%	25.13%	0.53x	1.11x	CN¥93.67 Million
2012	15.94%	25.25%	0.53x	1.20x	CN¥123.36 Million
2013	19.15%	28.72%	0.55x	1.22x	CN¥201.68 Million
2014	19.17%	30.34%	0.53x	1.20x	CN¥212.81 Million
2015	16.07%	27.07%	0.50x	1.18x	CN¥142.22 Million
2016	16.23%	25.81%	0.53x	1.18x	CN¥151.10 Million
2017	17.50%	28.74%	0.50x	1.22x	CN¥199.01 Million
2018	14.73%	26.08%	0.47x	1.21x	CN¥132.68 Million
2019	13.93%	23.90%	0.48x	1.21x	CN¥110.60 Million
2020	9.36%	17.68%	0.40x	1.31x	CN¥-18.88 Million
2021	12.10%	19.74%	0.43x	1.44x	CN¥59.74 Million
2022	11.71%	16.81%	0.49x	1.41x	CN¥48.19 Million
2023	14.96%	19.40%	0.55x	1.40x	CN¥139.60 Million
2024	17.33%	23.77%	0.52x	1.41x	CN¥220.56 Million

Industry Comparison

This section compares Guilin Sanjin Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $5,514,568,242
Average return on equity (ROE) among peers: 7.73%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Guilin Sanjin Pharmaceutical Co Ltd (002275)	CN¥3.24 Billion	31.46%	0.33x	$1.25 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$52.15 Million	21.80%	0.58x	$1.05 Billion
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$1.15 Billion	3.98%	1.16x	$438.59 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$10.00 Billion	4.41%	0.16x	$5.06 Billion
Livzon Pharmaceutical Group Inc (000513)	$1.04 Billion	4.86%	0.62x	$2.76 Billion
Wedge Industrial Co Ltd (000534)	$1.15 Billion	11.42%	1.59x	$2.94 Billion
Yunnan Baiyao Group Co Ltd (000538)	$38.10 Billion	10.98%	0.30x	$13.74 Billion
Hainan Haiyao Co Ltd (000566)	$2.20 Billion	-4.84%	2.35x	$958.72 Million
Tus Pharmaceutical Group Co Ltd (000590)	$579.72 Million	-6.59%	0.41x	$386.52 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$775.11 Million	6.08%	2.16x	$1.04 Billion
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$103.02 Million	25.18%	1.40x	$3.29 Billion

About Guilin Sanjin Pharmaceutical Co Ltd

SHE:002275 China Drug Manufacturers - Specialty & Generic

Market Cap

$1.25 Billion

CN¥8.51 Billion CNY

Market Cap Rank

#8251 Global

#2140 in China

Share Price

CN¥14.49

Change (1 day)

+0.62%

52-Week Range

CN¥13.35 - CN¥17.38

All Time High

CN¥19.61